Volume 28, Number 12—December 2022
CME ACTIVITY - Research
Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China
Wenchao Zhang1, Mei Yin1, Wei Li, Nana Xu, Haining Lu, Weidong Qin, Hui Han, Chen Li, Dawei Wu, and Hao Wang
Table 3
Multivariate analysis of risk factors for Acinetobacter baumannii among propensity-matched patient cohort during invasive mechanical ventilation, China*
| Variables | p value | Hazard ratio (95% CI) |
|---|---|---|
| Underlying conditions | ||
| Cardiovascular diseases | 0.117 | 1.361 (0.926–2.001) |
| Chronic renal insufficiency | 0.800 | 1.052 (0.712–1.554) |
| Type 2 diabetes mellitus | 0.243 | 1.271 (0.850–1.899) |
| Current or former smoker |
0.051 |
1.442 (0.998–2.083) |
| Treatment | ||
| Glucocorticoid aerosol inhalation | 0.032 | 1.489 (1.036–2.141) |
| Broad-spectrum antimicrobial drugs, >7 d | 0.004 | 6.315 (2.543–13.921) |
| Invasive mechanical ventilation, >5 d | <0.001 | 2.388 (1.614–3.534) |
| Vasopressor treatment, >3 d |
0.501 |
1.188 (0.719–1.963) |
| APACHE II score | 0.363 | 1.014 (0.984–1.045) |
*Only variables with p<0.1 in univariate analysis of the propensity-matched cohort were included. APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease.
1These authors contributed equally to this article.
Page created: October 17, 2022
Page updated: November 17, 2022
Page reviewed: November 17, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.